Prostate specific antigen in diagnosis, staging, and follow-up of prostate cancer.

Suppr

超能文献

作者信息

Cooper E H

机构信息

Department of Chemical Pathology, Leeds University, United Kingdom.

出版信息

Prostate Suppl. 1992;4:125-8. doi: 10.1002/pros.2990210520.

DOI:10.1002/pros.2990210520

PMID:1374175

Abstract

摘要

相似文献

Prostate specific antigen in diagnosis, staging, and follow-up of prostate cancer.

Prostate Suppl. 1992;4:125-8. doi: 10.1002/pros.2990210520.

Serum prostate-specific antigen: the most useful tumor marker.血清前列腺特异性抗原：最有用的肿瘤标志物。

J Clin Oncol. 1992 Aug;10(8):1205-7. doi: 10.1200/JCO.1992.10.8.1205.

Prostate-specific antigen. Improving its ability to diagnose early prostate cancer.

JAMA. 1992;267(16):2236-8. doi: 10.1001/jama.267.16.2236.

[Role of the markers PAP-PSA in the diagnosis of cancer of the prostate].

Minerva Urol Nefrol. 1990 Apr-Jun;42(2):73-5.

Re: Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate.

J Urol. 1990 Dec;144(6):1485-6. doi: 10.1016/s0022-5347(17)39781-1.

Clinical usefulness of prostate-specific antigen and prostatic acid phosphatase in patients with prostatic cancer.前列腺特异性抗原和前列腺酸性磷酸酶在前列腺癌患者中的临床应用价值。

Tumour Biol. 1990;11(6):289-94. doi: 10.1159/000217664.

Tissue polypeptide-specific antigen: a discriminative parameter between prostate cancer and benign prostatic hypertrophy.组织多肽特异性抗原：前列腺癌与良性前列腺增生之间的鉴别参数。

Eur J Cancer. 1993;29A(4):570-1. doi: 10.1016/s0959-8049(05)80153-4.

Prostate specific antigen.前列腺特异性抗原

Med Lett Drugs Ther. 1992 Oct 2;34(880):93-4.

[Emerging biomarkers for the diagnosis, staging and prognosis of prostate cancer].[前列腺癌诊断、分期及预后的新兴生物标志物]

Prog Urol. 2011 Jan;21(1):1-10. doi: 10.1016/j.purol.2010.07.004. Epub 2010 Aug 14.

Re: The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men.回复：游离前列腺特异性抗原与总前列腺特异性抗原的百分比、PCA3以及激肽释放酶检测指标对欧洲前列腺癌筛查随机对照试验（ERSPC）中前列腺癌预筛查男性风险计算器的附加价值。

J Urol. 2015 Jan;193(1):127. doi: 10.1016/j.juro.2014.10.074. Epub 2014 Oct 22.

引用本文的文献

Nadir PSA level and time to nadir PSA are prognostic factors in patients with metastatic prostate cancer.最低 PSA 水平和 PSA 降至最低水平的时间是转移性前列腺癌患者的预后因素。

BMC Urol. 2014 Apr 29;14:33. doi: 10.1186/1471-2490-14-33.

Outcomes and predictive factors for biochemical relapse following primary androgen deprivation therapy in men with bone scan negative prostate cancer.原发雄激素剥夺治疗后骨扫描阴性前列腺癌患者生化复发的结果和预测因素。

J Cancer Res Clin Oncol. 2011 Feb;137(2):235-41. doi: 10.1007/s00432-010-0877-9.

Gleason score and pretreatment prostate-specific antigen in survival among patients with stage D2 prostate cancer.D2期前列腺癌患者生存中的Gleason评分与治疗前前列腺特异性抗原

World J Urol. 2004 Dec;22(6):425-30. doi: 10.1007/s00345-004-0443-7. Epub 2004 Dec 8.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验